Palatin Technologies
Palatin Technologies is a clinical-stage biopharmaceutical company developing melanocortin receptor-targeted therapeutics, with its primary focus on MC4R agonists for rare obesity disorders and additional programs in dry eye, ulcerative colitis, retinal disease, and glaucoma.
- Company typePublic
- Founded1996
- HeadquartersCranbury, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Palatin Technologies does
Palatin Technologies is a clinical-stage biopharmaceutical company founded in 1996 and headquartered in Princeton, New Jersey (Nasdaq: PTN, transferring from NYSE American on May 29, 2026). The company develops first-in-class therapeutics based on modulation of the melanocortin receptor (MCR) system, with a primary strategic focus on MC4R-selective agonists for obesity — particularly rare neuroendocrine disorders including hypothalamic obesity, Prader-Willi syndrome, and Bardet-Biedl syndrome, where no approved pharmacologic treatments currently exist. Its lead candidates include PL7737, an oral MC4R agonist, and next-generation once-weekly injectable peptide MC4R agonists.
The company operates a five-receptor MCR agonist platform (MC1R–MC5R) that has produced a diversified pipeline: PL9643 (MC1R, dry eye disease — Phase 3, sublicensed to Altanispac Labs in January 2026), PL8177 (oral MC1R, ulcerative colitis — positive Phase 2 topline), PL9654 (MC1R, retinal diseases — licensed to Boehringer Ingelheim under a deal worth up to €280 million in milestones), and PL9588 (glaucoma, preclinical). Earlier asset Vyleesi (bremelanotide, HSDD) was divested to Cosette Pharmaceuticals in December 2023.
Palatin's business model is asset-light and partnership-driven: it monetizes its pipeline through licensing deals, milestone payments, and royalties rather than direct commercialization, while raising operating capital through registered direct and public equity offerings and New Jersey non-dilutive NOL funding. Following the Vyleesi divestiture, revenue has shifted to collaboration/license income, with Q3 FY2026 recording $3.9M from the Altanispac sublicensing and the Boehringer deal providing both upfront and milestone receipts. Cash and equivalents of $10.2M as of March 31, 2026 are projected to fund operations through June 2027, with the company returning to significantly narrowed net losses ($1.4M in Q3 FY2026 versus $4.8M prior year).
Palatin Technologies firmographics
Firmographics- Name
- Palatin Technologies
- Legal name
- Palatin Technologies, Inc.
- Website
- https://palatin.com
- Company type
- Public
- Founded year
- 1996
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Palatin Technologies is a clinical-stage biopharmaceutical company developing melanocortin receptor-targeted therapeutics, with its primary focus on MC4R agonists for rare obesity disorders and additional programs in dry eye, ulcerative colitis, retinal disease, and glaucoma.
- Ownership category
- akta.pro rank
Palatin Technologies industry classification
Industry- Product category
- Biopharmaceutical Therapeutics
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD)
- akta.pro secondary industry
- Ophthalmology Specialty Pharmaceuticals (HLAIACAK)
Keywords
Where Palatin Technologies is headquartered
LocationHeadquarters
- HQ city
- Cranbury
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Palatin Technologies business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Collaboration and License Revenue: Revenue from strategic partnerships including Boehringer Ingelheim retinal disease collaboration and Altanispac Labs PL9643 sublicensing. Includes upfront payments, research milestones, development milestones, regulatory milestones, commercial milestones, and tiered royalties on net sales.
- Public Offerings: Capital raised through registered direct offerings and public offerings of common stock and warrants to healthcare-focused institutional investors. Proceeds used for general corporate purposes and development of obesity program.
- Non-Dilutive Funding (NOL Program): New Jersey's Net Operating Loss program allowing biotech companies to sell net operating losses for cash. Received approximately $4.7 million in January 2023, with total non-dilutive funding under this program of about $18 million.
- Asset Sale (Vyleesi): Sale of Vyleesi worldwide rights for female sexual dysfunction to Cosette Pharmaceuticals for up to $171 million (December 2023).
Go-to-market motion2 records
Distribution channels1 record
Marketing channels5 records
Palatin Technologies product offering
Product offeringCore offering
Palatin Technologies is a clinical-stage biopharmaceutical company that discovers and develops first-in-class therapeutics based on modulation of the melanocortin receptor (MCR) system. Its pipeline includes MC4R agonists for rare neuroendocrine obesity disorders (PL7737 and next-generation peptides), MC1R agonists for dry eye disease (PL9643), ulcerative colitis (PL8177), and retinal diseases (PL9654), plus a topical MCR agonist for glaucoma (PL9588). The company commercializes assets primarily through licensing and collaboration agreements with larger pharmaceutical partners rather than direct sales.
Product overview
Palatin Technologies is a biopharmaceutical company developing first-in-class medicines based on melanocortin receptor modulation. The company's primary focus is on MC4R-based obesity programs targeting rare neuroendocrine disorders (hypothalamic obesity, Prader-Willi syndrome, Bardet-Biedl syndrome), with PL7737 as an oral small molecule candidate and next-generation peptide agonists for once-weekly injection. The portfolio includes PL9643 for dry eye disease (Phase 3, sublicensed to Altanispac Labs), PL8177 for ulcerative colitis (Phase 2), PL9654 for retinal diseases (licensed to Boehringer Ingelheim), and PL9588 for glaucoma. The company leverages a proprietary MCR agonist platform with receptor-selective design capabilities.
Differentiator
Problem solved
Functional benefit
Brands
- Vyleesi: FDA-approved treatment for hypoactive sexual desire disorder (HSDD), sold to Cosette Pharmaceuticals in December 2023.
Products and services
- PL7737
Quantifiable outcome
- Phase 3 MELODY-1 trial: 6 of 13 symptom endpoints showed statistically significant complete symptom resolution with PL9643 vs placebo (p<0.05)
- +3 more outcomes
Companies that use Palatin Technologies
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles3 records
Palatin Technologies technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Palatin Technologies partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- Altanispac LabscoreSublicensing agreement for MC1R agonist PL9643 for dry eye disease treatment. Palatin received $3.8 million in upfront consideration in January 2026, eligible for additional future payments including asset disposition and commercialization milestones, as well as royalties on net sales. Agreement sharpens focus on core obesity portfolio while preserving upside.
- Boehringer IngelheimcoreGlobal research collaboration and licensing agreement to develop first-in-class melanocortin receptor-targeted treatments for patients with retinal diseases including diabetic retinopathy and diabetic macular edema. Palatin received €2.0 million upfront and €5.5 million research milestone, eligible for up to €278 million in additional milestones plus tiered royalties on net sales. Boehringer focuses on addressing three main drivers of retinal disease: inflammation, vascular dysfunction, and neurodegeneration.
- Cosette PharmaceuticalscoreSale of Vyleesi worldwide rights for female sexual dysfunction to Cosette Pharmaceuticals for up to $171 million. Transaction completed in December 2023, with Palatin no longer recording product sales to pharmacy distributors.
Scale indicators8 records
Recent moves7 records
Expansion highlights5 records
Palatin Technologies competitors and assessment
Company assessmentDirect peers
- Rhythm Pharmaceuticals: Rhythm Pharmaceuticals develops MC4R agonists (setmelanotide) for rare genetic obesity disorders including Bardet-Biedl syndrome and POMC deficiency—the same MC4R pathway Palatin targets. Most directly comparable peer in melanocortin biology for rare obesity.
- Soleno Therapeutics: Soleno Therapeutics develops diazoxide choline extended-release (DCCR) for Prader-Willi syndrome, directly overlapping with one of Palatin's primary target indications. Same rare disease focus and orphan drug strategy.
- Crinetics Pharmaceuticals: Crinetics develops peptide therapeutics targeting endocrine GPCRs for rare endocrine disorders including acromegaly and congenital hyperinsulinism. Comparable small-cap clinical-stage peptide platform company with similar disease-area focus.
- Lexicon Pharmaceuticals: Lexicon Pharmaceuticals is a small-cap clinical-stage biotech focused on endocrine and metabolic disorders. Similar size, public listing, and rare disease specialty pharma positioning.
- Aldeyra Therapeutics: Aldeyra develops novel therapeutics for ocular inflammation (dry eye disease and allergic conjunctivitis), directly comparable to Palatin's PL9643 dry eye program. Similar small-cap clinical-stage ophthalmic biotech.
- BioLineRx: BioLineRx is a clinical-stage biopharmaceutical company developing novel peptide therapeutics for hematological and inflammatory diseases. Comparable size, business model, and partnership-driven revenue profile.
- Tempest Therapeutics: Tempest Therapeutics is a small-cap clinical-stage biotech with similar financing profile (multiple registered direct offerings, reverse stock considerations, partnership-dependent revenue). Comparable small-cap biotech peer structure.
Broad incumbents
- Madrigal Pharmaceuticals: Madrigal develops resmetirom (Rezdiffra) for metabolic dysfunction-associated steatohepatitis (MASH). Larger specialty pharma in metabolic disease space with approved product, providing peer benchmark for commercialization in metabolic indications.
- Zealand Pharma: Zealand Pharma develops peptide-based therapeutics for metabolic diseases including obesity. Larger European-listed peptide platform company providing benchmark for peptide therapeutic development in metabolic space.
Emerging players
- Structure Therapeutics: Structure Therapeutics develops oral peptide and small molecule GLP-1R agonists for obesity and metabolic disorders. Represents the broader competitive landscape in obesity therapeutics, with oral peptide platform approach similar to Palatin's oral MC4R strategy.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Palatin Technologies social profiles
Digital presencePalatin Technologies financial estimates
Financial estimateRevenue estimate
Valuation estimate
Palatin Technologies leadership team
Management profileNumber of profiles
Profiles1 record
Palatin Technologies subsidiaries and ownership
Company hierarchySubsidiaries1 record
Palatin Technologies funding detail
Funding detailFunding overview
Funding rounds13 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Palatin Technologies M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Palatin Technologies
What does Palatin Technologies do?
Palatin Technologies is a clinical-stage biopharmaceutical company that discovers and develops first-in-class therapeutics based on modulation of the melanocortin receptor (MCR) system. Its pipeline includes MC4R agonists for rare neuroendocrine obesity disorders (PL7737 and next-generation peptides), MC1R agonists for dry eye disease (PL9643), ulcerative colitis (PL8177), and retinal diseases (PL9654), plus a topical MCR agonist for glaucoma (PL9588). The company commercializes assets primarily through licensing and collaboration agreements with larger pharmaceutical partners rather than direct sales.
Is Palatin Technologies a public or private company?
Palatin Technologies is a public company. It is classified as public and is currently operating.
When was Palatin Technologies founded?
Palatin Technologies was founded in 1996. It employs 11 to 50 people.
Where is Palatin Technologies based?
Palatin Technologies is headquartered in Cranbury, United States, in the North America region.
How does Palatin Technologies make money?
Four revenue lines are on record. Collaboration and License Revenue is the primary driver. The others are public Offerings, non-Dilutive Funding (NOL Program) and asset Sale (Vyleesi).
Who are Palatin Technologies's main competitors?
Direct peers on record are Rhythm Pharmaceuticals, Soleno Therapeutics, Crinetics Pharmaceuticals, Lexicon Pharmaceuticals, Aldeyra Therapeutics, BioLineRx and Tempest Therapeutics. Broad incumbents are Madrigal Pharmaceuticals and Zealand Pharma. Structure Therapeutics is listed as an emerging player.
Does Palatin Technologies have an API?
No public API is recorded for Palatin Technologies.
What industry is Palatin Technologies in?
Palatin Technologies's product category is Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAIACAD, Endocrinology & Metabolic Specialty Pharmaceuticals, with a secondary code of HLAIACAK, Ophthalmology Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.